Navigation Links
New Treatments Hold Hope for Failing Eyes
Date:9/27/2009

As the U.S. ages, macular degeneration rates are expected to swell

SUNDAY, Sept. 27 (HealthDay News) -- Already a leading cause of vision loss among people older than 60, age-related macular degeneration is expected to skyrocket in numbers over the coming decades as the U.S. population grows older.

However, a series of new treatments now under study or in development should mean that eye specialists will be well-prepared to treat the coming surge of macular degeneration cases.

These include refinements of treatments that have proven effective against some forms of the disease as well as new therapies targeting forms of macular degeneration that have so far proven impossible to treat.

Age-related macular degeneration involves the breakdown of the macula, which is located in the retina and helps provide clear central vision. As the macula deteriorates, people see a blurred spot in the center of their vision that grows over time.

Macular degeneration comes in two forms, wet and dry. Current treatments for the wet form of the disease -- in which abnormal new blood vessels in the eye cause leakage and bleeding -- have proven quite successful. The wet form is more rare but can cause rapid vision loss if not caught early.

Researchers have discovered a combination therapy of vitamins and antioxidants that reduces the risk of progressive vision loss by more than 20 percent, said Dr. David W. Parke II, executive vice president and chief executive of the American Academy of Ophthalmology.

Other progress against the wet form of the disease has come through the use of drugs that target vascular endothelial growth factor, or VEGF, a substance in the body that promotes the growth of new blood vessels.

"We now have treatments where, when we catch people early in the course of the disease, the chance of vision loss is less than 10 percent over a two-year period," said George Williams, chairman of ophthalmology and director of the Eye Institute at William Beaumont Hospital in Royal Oak, Mich. Those treatments also provide a 20 to 30 percent chance of significant vision improvement over the same period.

No effective treatments have been found for the dry form of macular degeneration, which causes less catastrophic vision loss but accounts for 85 percent of all macular degeneration cases, according to the U.S. National Eye Institute. The dry form occurs when the light-sensitive cells in the macula begin to slowly break down.

New advances in the treatment of the wet form involve further research into vitamin combinations that can help slow the progress of macular degeneration, Parke said. An ongoing trial is looking into whether diet or supplements can better improve a person's chances of retaining clear vision late in life.

"Around the world, there are culturally different rates of progression," Parke said. "The question becomes, how much of this is dietary?"

Research also has focused on the two drugs currently used to target VEGF, with a head-to-head study now looking into which of the two is more effective. "It's a very important trial, and I think all involved are looking forward to seeing if these drugs have a lot of differences," Parke said.

Other anti-VEGF drugs are in the pipeline, Williams said, and studies are testing ways to combine anti-VEGF medications with radiation or laser therapy to produce better results.

Cutting-edge research also may have found another way to tackle the wet form of macular degeneration. In the June 14 issue of Nature, doctors reported that blocking the activity of a specific protein can reduce the same blood vessel growth that leads to the wet form.

"We now have the opportunity to develop drugs that target this protein that may be safer and more effective than our current treatments," Parke said.

As far as the dry form of macular degeneration, eye experts are exploring ways that drugs used to treat other nerve-damaging diseases such as Alzheimer's might be able to help save people's eyesight, Williams said.

"We're fairly optimistic that within three to five years we'll have a treatment for the dry form of macular degeneration," he said. "We know what happens is the nerve cells that sense the light are dying off. The thought here is if we attack the process that makes them die, we can save the vision."

More information

The U.S. National Eye Institute has more on macular degeneration.



SOURCES: David W. Parke II, M.D., executive vice president and chief executive, American Academy of Ophthalmology; George Williams, M.D., chairman of ophthalmology, and director, Beaumont Eye Institute, William Beaumont Hospital, Royal Oak, Mich.; U.S. National Eye Institute


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. National Autism Center Releases Groundbreaking Report on Autism Treatments
2. Women's Pelvic Organ Prolapse and Incontinence Guide Informs, Outlines Treatments
3. A Dementia That Afflicts Younger Population Has Similarities to Alzheimers, Applicable Treatments
4. Guatemala Treatment Center Becomes First in Latin America to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments
5. Florida Clinicians Now Delivering Non-Invasive Image-Guided Treatments Using Novalis Tx(TM) Radiosurgery Technology
6. Weighing costs, benefits of HIV treatments
7. Cash For Crows Feet Program Offers Effective - and Affordable - Laser Skin Treatments
8. Reportlinker Adds Liver Disease Treatments: The Global Market Report
9. Two Treatments Equally Effective for Chronic Pelvic Pain
10. Are intravenous treatments safe? New research raises doubts
11. Los Angeles Clinic (laserandveinclinic.com) Offers the Latest Laser Skin Rejuvenation Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Treatments Hold Hope for Failing Eyes
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology: